Pleiotropic effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in pulmonary diseases: a comprehensive review

Pulm Pharmacol Ther. 2015 Feb:30:134-40. doi: 10.1016/j.pupt.2014.08.006. Epub 2014 Aug 27.

Abstract

The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) are used extensively in the treatment of hyperlipidemia. They have also demonstrated a secondary benefit in a variety of other disease processes, actions which are known as pleiotropic effects. Review of the current pulmonary literature suggests a potential advantage of statin usage in a variety of pulmonary conditions. Our paper serves as a focused discussion on the pleiotropic effects of statins in the most common pulmonary disorders.

Keywords: Comprehensive review; Pleiotropic effects; Pulmonary disease; Statins.

Publication types

  • Review

MeSH terms

  • Animals
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Hyperlipidemias / drug therapy
  • Lung Diseases / drug therapy*
  • Lung Diseases / physiopathology

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors